CTOs on the Move

Precision IBD

www.precisionibd.com

 
Precision IBD, Inc. is a biopharmaceutical company focused on the discovery an development of a broad portfolio of precision therapeutics and companion diagnostics for inflammatory bowel disease.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

OcuSense

OcuSense is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avalon Pharmaceuticals

Avalon Pharmaceuticals , Inc. is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gossamer Bio

Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio`s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need,

Yourgene Health

Yourgene Health, an integrated technologies and services business, enabling the delivery of genomic medicine. Our Expertise: Yourgene has >10 years of experience and expertise in liquid biopsy through NIPT, sample preparation and now precision medicine.

Axcella Health

Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.